3177 results for «386»
3177 results
Featured research - Tricuspid valve intervention: the TRIPLACE registry
17 Nov 2025 – From PCR London Valves 2025
This session features cutting-edge research on tricuspid valve interventions, including insights from the TRIPLACE registry on orthotopic TTVR thrombosis, predictive value of three-dimensional tricuspid annulus measurements for procedural outcomes, early clinical experiences with novel TTVR systems, and procedural clipping strategies based on results from the BRIGHT...
Left atrial appendage occlusion
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities and innovations in left atrial appendage occlusion (LAAO) procedures. It covers transesophageal ICE monitoring, challenges posed by existing atrial septal occluders, combined surgical and percutaneous approaches, and the practical experience with the Ultraseal device. These insights advance understanding of procedural...
Featured research - TAVI: Predictive tools, AI innovation and reintervention strategies
17 Nov 2025 – From PCR London Valves 2025
This session presents cutting-edge research in TAVI, covering the development of predictive models for clinical valve thrombosis, comparative analyses between self-expandable and balloon-expandable valves from the Greek TAVI registry, and the emerging role of AI-guided Heart Team decisions. It also examines outcomes of reintervention strategies following...
TAVI: complex vascular access
17 Nov 2025 – From PCR London Valves 2025
This session addresses the challenges of complex vascular access in transcatheter aortic valve implantation (TAVI). It discusses strategies for navigating difficult thoraco-abdominal aortic anatomies, managing double aortic arches, and overcoming hostile femoral access. Case studies illustrate meticulous planning and innovative solutions essential for successful TAVI in...
TAVI valve-in-valve - Challenging clinical scenarios
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities of valve-in-valve TAVI procedures, highlighting challenging clinical scenarios such as managing severely regurgitant rapid deployment valves and degenerated stentless bioprostheses. It provides detailed insights into overcoming procedural barriers and strategies for complex valve-in-valve transcatheter aortic valve replacement (TAVR) interventions.
TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture
17 Nov 2025 – From PCR London Valves 2025
This session presents critical case analyses of complicated TAVI procedures, highlighting unexpected and severe intra-procedural events such as annular perforation, leaflet modification complications, coronary obstructions, and device failures. It emphasizes prevention strategies, bailout techniques, and acute management to prepare clinicians for handling TAVI-related emergencies effectively.
TAVI: alternative access
17 Nov 2025 – From PCR London Valves 2025
This session addresses alternative access routes for TAVI in patients with challenging vascular anatomies. It includes innovative approaches such as transapical TAV-in-TAV procedures, transcaval implantation in emergency settings, and techniques for patients with hostile iliofemoral access, showcasing adaptive strategies when conventional access is not feasible.
TAVI: challenging anatomies
17 Nov 2025 – From PCR London Valves 2025
This session explores the management of challenging anatomical conditions in TAVI procedures. Topics include strategies for difficult self-expandable valve delivery angles, addressing complications occurring during and after TAVI, and approaches for patients with severe kyphosis or complex structural abnormalities such as aneurysms and septal anomalies.
Challenging mitral TEER: Barlow's disease, fibro-elastic deficiency & abnormal valve morphology
17 Nov 2025 – From PCR London Valves 2025
This session examines the feasibility and technical considerations of mitral transcatheter edge-to-edge repair (TEER) in complex anatomical and pathological scenarios. Topics include applications in Barlow's disease, fibro-elastic deficiency, congenital heart anomalies, Anderson-Fabry disease, and post-cardiac transplantation, providing valuable insights into expanding TEER indications and overcoming anatomical...
Mitral interventions in shock
17 Nov 2025 – From PCR London Valves 2025
This session highlights the intricacies of mitral valve interventions in the context of cardiogenic shock. It addresses complex cases including left-to-right shunts post septal puncture, severe ischemic mitral insufficiency with small valve anatomy, emergency mitral TEER for papillary muscle rupture, and bridging strategies to surgery.
Tricuspid valve interventions in complex scenarios - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session delves into transcatheter interventions for the tricuspid valve in complex clinical scenarios. It covers techniques for native annular reduction via TEER, management of lead-related regurgitation, challenging cases of torrential regurgitation with device detachment, and innovative methods facilitating valve-in-ring implantation, enhancing procedural efficacy in tricuspid...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
Fractional flow reserve-guided complete or culprit-only PCI in patients with ST-elevation myocardial Infarction - FULL REVASC
08 Apr 2024
Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.
The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...
Author
A review of the 2024 ESC Guidelines on elevated blood pressure and hypertension
13 Nov 2024
Lucas Lauder and Felix Mahfoud provide a summary of the ESC Guidelines on elevated blood pressure and hypertension presented by John William McEvoy and Rhian Touyz at ESC Congress 2024 in London.
Author
Author
OPTION-STEMI: Immediate versus staged complete revascularisation during index admission in patients with STEMI and multivessel disease
02 Sep 2025
Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.
Author
